MALVERN, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the pricing of its previously announced underwritten public offering of its common stock, comprised of 18,750,000 shares of common stock at a public offering price of $1.60 per share. The gross proceeds to the Company from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company..

宾夕法尼亚州马尔文，2026年11月10日（环球电讯社）——Neuronetics, Inc.（纳斯达克股票代码：STIM）（“公司”）今日宣布其先前宣布的普通股包销公开发行的定价，此次发行包括18,750,000股普通股，公开发行价格为每股1.60美元。在扣除承销折扣和佣金以及公司应付的其他发行费用之前，公司从此次发行中获得的总收益预计约为3,000万美元。

The Company also granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares in the offering are being sold by the Company. The Company intends to use a portion of the net proceeds from this offering to repay a portion of the outstanding term loan under the Company’s Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Credit Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures.

本公司还授予承销商一项为期30天的选择权，可按每股公开发行价格减去承销折扣和佣金后的价格，额外购买最多2,812,500股普通股。本次发行中的所有股份均由本公司出售。本公司拟将本次发行所得净收益的一部分用于偿还其与Perceptive Credit Holdings IV, LP（“信贷设施”）签订的经修订的《信贷协议及担保》项下未偿还定期贷款的一部分，其余部分用于一般公司用途，包括但不限于销售与市场推广、研发活动、为潜在收购或建立医疗实践提供融资、库存采购、一般及行政事务、营运资金以及资本支出。

The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions..

预计本次发行将于2026年11月12日或左右完成，但须满足惯例交割条件。

As previously disclosed, on November 5, 2026, the Company entered into an Amendment No. 6 to the Credit Facility (the “Perceptive Sixth Amendment”), which amends the Credit Facility to, among other things, reduce certain revenue covenants, subject to certain conditions precedent, including, among other things, a prepayment of no less than $15,000,000, together with accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and payment of the lender parties’ other costs and expenses.

正如先前披露，公司于2026年11月5日签署了《信贷设施第六号修正案》（“Perceptive第六修正案”），该修正案对信贷设施进行了修订，其中包括在满足某些先决条件的前提下降低某些收入契约要求，这些先决条件包括但不限于：预付不少于15,000,000美元，连同应计但未付的利息以及适用的提前还款费用，外加适用的修正费用及支付贷款方其他成本和费用。

If such conditions are not satisfied or waived on or before November 30, 2026, the Perceptive Sixth Amendment will automatically terminate. The Company anticipates that, if the conditions precedent in the Perceptive Sixth Amendment are satisfied, the reduction of those revenue covenants will resolve the going concern risk referenced in the Company’s recent Form 10-Q filings..

如果上述条件在2026年11月30日或之前未得到满足或豁免，Perceptive第六修正案将自动终止。公司预计，如果Perceptive第六修正案中的先决条件得到满足，对这些收入契约的放宽将解决公司近期10-Q表格文件中提到的持续经营风险。

William Blair is acting as the lead bookrunning manager for the offering. BTIG and Canaccord Genuity are acting as additional bookrunners for the offering.

William Blair 担任此次发行的主簿记管理人。BTIG 和 Canaccord Genuity 担任此次发行的附加簿记管理人。

A shelf registration statement relating to the common stock being sold in this offering was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 3, 2025, and was declared effective on July 18, 2025. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that form part of the registration statement.

与本次发行中出售的普通股相关的货架注册声明已于2025年7月3日向美国证券交易委员会（“SEC”）提交，并于2025年7月18日被宣布生效。本次发行仅通过构成该注册声明一部分的招股说明书补充文件及随附的招股说明书进行。

A preliminary prospectus supplement relating to and describing the terms of the offering and accompanying prospectus has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC.

一份与本次发行相关并描述其条款的初步招股说明书补充文件及随附的招股说明书已提交给美国证券交易委员会（SEC），并可在美国证券交易委员会网站（http://www.sec.gov）上获取。与本次发行相关的最终招股说明书补充文件及随附的招股说明书也将提交给美国证券交易委员会。

When available, copies of the final prospectus supplement and accompanying prospectus can be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC..

如有提供，最终招股说明书补充文件及随附的招股说明书副本可从 William Blair & Company, L.L.C. 获取，联系地址为：Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606；联系电话：(800) 621-0687；电子邮箱：prospectus@williamblair.com。发行的最终条款将在向美国证券交易委员会（SEC）提交的最终招股说明书补充文件中披露。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction..

本新闻稿不构成出售要约或征求购买这些证券的要约，也不会在任何司法管辖区进行这些证券的销售，如果在该司法管辖区根据证券法进行注册或资格认定之前，此类要约、征求或销售是非法的。

About Neuronetics

关于 Neuronetics

Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar Advanced Therapy System, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc.

Neuronetics, Inc. 是介入式精神健康领域的领导者，将创新治疗技术与直接患者护理相结合。通过其 NeuroStar 高级治疗系统，该公司是经颅磁刺激（“TMS”）治疗的领先提供商，并通过 Greenbrook TMS Inc.

(“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped.

（“Greenbrook”）运营着美国最大的介入精神病学诊所网络之一，提供经颅磁刺激（TMS）和SPRAVATO®疗法。NeuroStar高级疗法是一种非药物、无创的治疗方式，当传统药物治疗无效时，它可以改善患有神经健康疾病患者的生活质量。

NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant.

NeuroStar高级疗法是成人重度抑郁症（“MDD”）的领先经颅磁刺激（TMS）治疗方案，并拥有我们认为在任何用于抑郁症的TMS治疗系统中最大的临床数据集。Greenbrook治疗中心还提供SPRAVATO（艾氯胺酮）鼻喷雾剂，这是一种处方药，适用于成人治疗难治性抑郁症（“TRD”），可作为单药治疗或与口服抗抑郁药联合使用。

It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant..

本品亦适用于伴有急性自杀意念或行为的成人重度抑郁症（MDD）患者的抑郁症状，需与口服抗抑郁药联合使用。

1

1

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21.

NeuroStar 高级治疗系统已获得美国食品药品监督管理局批准，用于患有重度抑郁症（MDD）的成人；作为患有强迫症的成人的辅助治疗手段；用于减轻可能伴有共病性焦虑症状（即焦虑性抑郁）的 MDD 成年患者的焦虑症状；并作为 15 至 21 岁青少年 MDD 患者的一线辅助治疗手段。

For safety information and indications for use, visit NeuroStar.com..

有关安全信息和使用适应症，请访问 NeuroStar.com。

Safe Harbor / Forward-Looking Statements

安全港声明 / 前瞻性陈述

Certain statements in this press release include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created by those laws and other applicable laws and “forward-looking information” within the meaning of applicable Canadian securities laws.

本新闻稿中的某些陈述包含经修订的《1933年证券法》第27A条和经修订的《1934年证券交易法》第21E条所定义的“前瞻性陈述”，以及适用加拿大证券法律所定义的“前瞻性信息”，这些陈述和信息旨在受上述法律及其他适用法律所设立的安全港条款的保护。

Statements in this press release that are not historical facts constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by terms such as “may,” “will,” “would,” “should,” “expect,” “plan,” “design,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “outlook” or “continue” as well as the negative of these terms and similar expressions.

本新闻稿中非历史事实的陈述构成1995年《私人证券诉讼改革法》意义上的“前瞻性陈述”。这些前瞻性陈述可以通过诸如“可能”、“将”、“将会”、“应该”、“预期”、“计划”、“设计”、“预计”、“能够”、“打算”、“目标”、“规划”、“考虑”、“相信”、“估计”、“预测”、“潜在”、“展望”或“继续”等词语以及这些词语的否定形式和类似表述来识别。

Forward-looking statements in this press release include, but are not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering, anticipated closing of the offering, the gross proceeds, the intended use of proceeds, including the prepayment of a portion of the outstanding term loan under the Credit Facility with Perceptive Credit Holdings IV, LP, the satisfaction of the conditions precedent to the effectiveness of the Perceptive Sixth Amendment, and the completion of the offering on the anticipated terms or at all.

本新闻稿中的前瞻性陈述包括但不限于，有关提交与本次发行相关的最终招股说明书补充文件及随附招股说明书的陈述、预期的发行交割、募集资金总额、募集资金的预期用途（包括预偿与Perceptive Credit Holdings IV, LP签订的信贷安排项下部分未偿还定期贷款）、满足Perceptive第六修正案生效的先决条件，以及按预期条款或完全完成本次发行。

There can be no assurance that this offering will close or that the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those projecte.

无法保证本次发行能够完成，也无法保证公司能够从中获得净收益。存在众多风险和不确定性，可能导致实际结果以及公司的计划和目标与预期产生重大差异。

Investor Contact:

投资者联系：

Mark Klausner

马克·克劳斯纳

ICR Healthcare

ICR 医疗

443-213-0499

443-213-0499

ir@neuronetics.com

ir@neuronetics.com

Media Contact:

媒体联系人：

EvolveMKD

EvolveMKD

646-517-4220

646-517-4220

NeuroStar@evolvemkd.com

NeuroStar@evolvemkd.com